
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with the rare airway disease.
Top articles of the week from Specialty Pharmacy Times.
[<a href="//storify.com/pharmacytimes/customer-satisfaction-awards-highlight-specialty-p" target="_blank">View the story "Customer Satisfaction Awards Highlight Specialty Pharmacy Week in Review" on Storify</a>]






